Completed PHASE4 INTERVENTIONAL 1-arm NCT05387967

Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction

Sponsor: National Institute of Cardiovascular Diseases, Pakistan

Updated 4 times since 2022 Last updated: May 20, 2022 Started: Jan 1, 2021 Primary completion: Jun 30, 2021 Completion: Sep 30, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Heart Failure, Systolic and is currently completed. National Institute of Cardiovascular Diseases, Pakistan leads this study, which shows 4 recorded versions since 2021 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Apr 2023 — Jul 2024 [monthly]

Completed PHASE4
Jun 2022 — Apr 2023 [monthly]

Completed PHASE4

First recorded

Jan 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Cardiovascular Diseases, Pakistan

Data source: National Institute of Cardiovascular Diseases, Pakistan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Karachi, Pakistan